Suppr超能文献

1993年头孢吡肟与几种抗菌药物对从加拿大各地患者中分离出的需氧革兰氏阴性菌和革兰氏阳性菌的比较活性。

Comparative activity of cefepime with several antimicrobials against aerobic Gram-negative and Gram-positive organisms isolated from patients across Canada in 1993.

作者信息

Low D E

机构信息

Department of Microbiology, Mount Sinai and Princess Margaret Hospitals, University of Toronto, Toronto, Ontario.

出版信息

Can J Infect Dis. 1995 Sep;6(5):258-62. doi: 10.1155/1995/458762.

Abstract

To compare the activity of cefepime, a fourth-generation cephalosporin, with several available antimicrobials, in vitro susceptibility studies were carried out on bacteria commonly associated with various infections, including sepsis. Ten tertiary care hospital laboratories in six provinces provided 1276 clinically relevant isolates of aerobic Gram-negative bacilli and Gram-positive cocci during 1993. When the activity of each of the antimicrobials was determined against all isolates submitted, cefepime, piperacillin/tazobactam, imipenem and ciprofloxacin all had minimal inhibitory concentrations for 90% of the organisms (mic(90)) two or more dilutions below the mic resistant category. Gentamicin's mic(90) against all organisms tested was one dilution below the mic resistant category. The mic(90)s of the third-generation cephalosporins, piperacillin and ticarcillin/clavulanate, for Enterobacter species fell in the resistant category. This is presumably due to constitutive high level chromosomal cephalosporinase production. The mic(90)s of cefepime for Enterobacter species was three or more dilutions below the mic resistant category. The mic(90)s of all antimcrobials against Staphylococcus aureus, with the exception of ceftazidime and piperacillin, had mic(90) categories two or more dilutions below the resistant category. The activity of cefepime, piperacillin/tazobactam, imipenem, ciprofloxacin and gentamicin make them excellent candidates for the empirical therapy of serious infections due to aerobic Gram-negative bacilli and S aureus.

摘要

为比较第四代头孢菌素头孢吡肟与几种现有抗菌药物的活性,对常见于包括败血症在内的各种感染的细菌进行了体外药敏研究。1993年,六个省份的十家三级护理医院实验室提供了1276株具有临床相关性的需氧革兰氏阴性杆菌和革兰氏阳性球菌分离株。当测定每种抗菌药物对所有提交的分离株的活性时,头孢吡肟、哌拉西林/他唑巴坦、亚胺培南和环丙沙星对90%的菌株的最低抑菌浓度(mic(90))比耐药类别低两个或更多稀释度。庆大霉素对所有测试菌株的mic(90)比耐药类别低一个稀释度。第三代头孢菌素、哌拉西林和替卡西林/克拉维酸对肠杆菌属的mic(90)处于耐药类别。这可能是由于染色体头孢菌素酶的组成型高水平产生。头孢吡肟对肠杆菌属的mic(90)比耐药类别低三个或更多稀释度。除头孢他啶和哌拉西林外,所有抗菌药物对金黄色葡萄球菌的mic(90)类别比耐药类别低两个或更多稀释度。头孢吡肟、哌拉西林/他唑巴坦、亚胺培南、环丙沙星和庆大霉素的活性使其成为治疗由需氧革兰氏阴性杆菌和金黄色葡萄球菌引起的严重感染的经验性治疗的优秀候选药物。

相似文献

本文引用的文献

1
In-vitro antibacterial activity of cefepime: a multicentre study.
J Antimicrob Chemother. 1993 Nov;32 Suppl B:55-61. doi: 10.1093/jac/32.suppl_b.55.
2
In-vitro activity of cefepime and other antimicrobials: survey of European isolates.
J Antimicrob Chemother. 1993 Nov;32 Suppl B:31-53. doi: 10.1093/jac/32.suppl_b.31.
3
Quality standard for the treatment of bacteremia. Infectious Diseases Society of America.
Clin Infect Dis. 1994 Mar;18(3):428-30. doi: 10.1093/clinids/18.3.428.
4
beta-Lactamases and beta-lactam resistance in Escherichia coli.
Antimicrob Agents Chemother. 1985 Nov;28(5):703-5. doi: 10.1128/AAC.28.5.703.
5
Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.
Antimicrob Agents Chemother. 1985 May;27(5):679-82. doi: 10.1128/AAC.27.5.679.
6
Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.
Antimicrob Agents Chemother. 1985 Feb;27(2):207-16. doi: 10.1128/AAC.27.2.207.
8
In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.
Antimicrob Agents Chemother. 1985 Apr;27(4):515-9. doi: 10.1128/AAC.27.4.515.
10
Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy.
Antimicrob Agents Chemother. 1986 May;29(5):845-8. doi: 10.1128/AAC.29.5.845.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验